Quantcast
Home > Quotes > OMER
OMER

Omeros Corporation Common Stock (OMER) Quote & Summary Data

$22.07
*  
1.15
5.5%
Get OMER Alerts
*Delayed - data as of Aug. 20, 2018  -  Find a broker to begin trading OMER now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 22.25 / $ 20.92
Share Volume
610,567
50 Day Avg. Daily Volume
575,147
Previous Close
$ 20.92
52 Week High / Low
$ 25.20 / $ 8.36
Market Cap
1,065,817,859
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
610,567
50 Day Avg. Daily Volume:
575,147

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.82

Trading Range

The current last sale of $22.07 is 164.00% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 22.25 $ 25.20
 Low: $ 20.92 $ 8.36

ETFs with OMER as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
1.27% SPDR S&P Pharmaceuticals ETF (XPH) +7.75 (18.83%)
1.05% iShares U.S. Pharmaceutical ETF (IHE) +21.92 (15.04%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

We are a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system. Our drug product OMIDRIA┬« is marketed in the U.S. for use during cataract surgery or intraocular lens, or IOL, replacement. In our pipeline we have clinical-stage development programs focused on: complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; Huntington's disease and cognitive impairment; and addictive and compulsive disorders. In addition, we have a diverse group of preclinical programs and two platforms: one capable of unlocking new G protein-coupled receptor, or GPCR, drug targets and the other used to generate antibodies.  ... More ...  


Risk Grade

Where does OMER fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 20.92
Open Date:
Aug. 20, 2018
Close Price:
$ 22.07
Close Date:
Aug. 20, 2018

Consensus Recommendation

Analyst Info